CA2333157A1 - Nouveaux composes d'imidazole substitue - Google Patents

Nouveaux composes d'imidazole substitue Download PDF

Info

Publication number
CA2333157A1
CA2333157A1 CA002333157A CA2333157A CA2333157A1 CA 2333157 A1 CA2333157 A1 CA 2333157A1 CA 002333157 A CA002333157 A CA 002333157A CA 2333157 A CA2333157 A CA 2333157A CA 2333157 A1 CA2333157 A1 CA 2333157A1
Authority
CA
Canada
Prior art keywords
alkyl
heterocyclic
hydrogen
disease
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002333157A
Other languages
English (en)
Inventor
Jerry Leroy Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2333157A1 publication Critical patent/CA2333157A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

L'invention concerne de nouveaux composés d'imidazole 1,4,5-substitué et des compositions destinées à être utilisées comme inhibiteurs d'ERK/MAP dans des affections induites par ERK/MAP.
CA002333157A 1998-05-26 1999-05-25 Nouveaux composes d'imidazole substitue Abandoned CA2333157A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8664598P 1998-05-26 1998-05-26
US60/086,645 1998-05-26
PCT/US1999/011455 WO1999061440A1 (fr) 1998-05-26 1999-05-25 Nouveaux composes d'imidazole substitue

Publications (1)

Publication Number Publication Date
CA2333157A1 true CA2333157A1 (fr) 1999-12-02

Family

ID=22199934

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002333157A Abandoned CA2333157A1 (fr) 1998-05-26 1999-05-25 Nouveaux composes d'imidazole substitue

Country Status (4)

Country Link
EP (1) EP1082320A4 (fr)
JP (1) JP2002516325A (fr)
CA (1) CA2333157A1 (fr)
WO (1) WO1999061440A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1023066A4 (fr) 1997-06-13 2001-05-23 Smithkline Beecham Corp Nouveaux composes de pyrazole et de pyrazoline substitues
EP0994870A4 (fr) 1997-06-19 2002-10-23 Smithkline Beecham Nouveaux composes imidazole a substitution d'aryloxypymiridine
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
JP2001518507A (ja) 1997-10-08 2001-10-16 スミスクライン・ビーチャム・コーポレイション 新規シクロアルケニル置換化合物
EP1112070B1 (fr) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Nouveaux composes de triazole substitues
HUP0104693A3 (en) * 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
JP2003514899A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４‐ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
ZA200301696B (en) 2000-09-15 2004-04-28 Vertex Pharma Isoxazoles and their use as inhibitors of erk.
WO2002072576A1 (fr) 2001-03-09 2002-09-19 Pfizer Products Inc. Composes de benzimidazole anti-inflammatoires
CN1496366A (zh) 2001-03-09 2004-05-12 �Ʒ� 作为抗炎剂的***并吡啶
DE60205974T2 (de) 2001-04-04 2006-06-29 Pfizer Products Inc., Groton Neue Benzotriazole mit entzündungshemmender Wirkung
EP1707205A2 (fr) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Compositions pharmaceutiques contenant un antichlinergique et un inhibiteur du p38 pour le traitement de maladies respiratoires
JP2006508051A (ja) 2002-08-29 2006-03-09 サイオス インク． 骨形成を促進する方法
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
EP1598079B1 (fr) * 2003-02-26 2009-04-22 Kowa Co., Ltd. Traitement de la dermatite de contact allergique
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20060166936A1 (en) * 2004-10-29 2006-07-27 Hayley Binch Diaminotriazole compounds useful as inhibitors of protein kinases
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (fr) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Procédé favorisant la survie des tissus ou cellules griffées
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
BRPI0919919A2 (pt) 2008-10-21 2017-05-30 Massachusetts Gen Hospital transplante celular
AU2010231514A1 (en) * 2009-04-01 2011-11-03 Rappaport Family Institute For Research In The Medical Sciences A method of regulating proliferation and differentiation of keratinocytes
JP6072684B2 (ja) 2010-08-06 2017-02-01 ザ ジェネラル ホスピタル コーポレーション ディー／ビー／エイ マサチューセッツ ジェネラル ホスピタル 細胞処置システムおよび細胞処置装置
TW202102511A (zh) 2019-03-28 2021-01-16 大陸商江蘇恆瑞醫藥股份有限公司 噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用
KR20210146956A (ko) 2019-03-29 2021-12-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤로헤테로고리형 유도체, 이의 제조 방법, 및 의약에서 이의 응용
US20220204512A1 (en) 2019-05-24 2022-06-30 Jiangsu Hengrui Medicine Co., Ltd. Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines
KR20230079120A (ko) 2020-09-29 2023-06-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 피롤로 헤테로고리계 유도체의 결정형 및 이의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1998016230A1 (fr) * 1996-10-17 1998-04-23 Smithkline Beecham Corporation Procedes permettant d'inhiber de maniere reversible la myelopoiese dans des tissus mammaliens

Also Published As

Publication number Publication date
JP2002516325A (ja) 2002-06-04
WO1999061440A1 (fr) 1999-12-02
EP1082320A4 (fr) 2001-11-21
EP1082320A1 (fr) 2001-03-14

Similar Documents

Publication Publication Date Title
CA2333157A1 (fr) Nouveaux composes d'imidazole substitue
ES2316546T3 (es) 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
KR100417779B1 (ko) 치환된 벤즈이미다졸 및 ｐａｒｐ 억제제로서 그의 용도
EP1966184B1 (fr) Derives de pyridinyl-quinazoline et leur utilisation medicale
JP2019081815A (ja) 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤
AU767558B2 (en) Aromatic nitrogenous six-membered ring compounds
EP1558607B1 (fr) Compositions utiles en tant qu'inhibiteurs de rock et d'autres proteines kinases
JP5240899B2 (ja) トリアゾロフタラジン
TWI335913B (en) Diaminotriazoles useful as inhibitors of protein kinases
EP1861388B1 (fr) Agents modulateurs du canal potassique et leur utilisation medicale
US11939297B2 (en) Cannabinoid receptor mediating compounds
WO2005039564A1 (fr) Composes phtalimide utiles en tant qu'inhibiteurs de proteine kinase
JP2003522163A (ja) Ｅｒｋのインヒビターとして有用なピラゾール組成物
WO2012072033A1 (fr) Composés 2,3-phtalazinone substitués et leur utilisation
US20190352268A1 (en) Cannabinoid receptor mediating compounds
AU5551899A (en) Prodrugs of proton pump inhibitors
TW200410963A (en) Heterocyclic derivatives
JP2009543843A (ja) 直接トロンビン阻害剤に関する新規適応
JPH10508847A (ja) 酸化窒素合成酵素インヒビターとして有用なアミノテトラゾール誘導体
JP2002528506A (ja) ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン
TW200526627A (en) New compounds
US20160075683A1 (en) Novel heterocycle compounds and uses thereof
EP1679073A1 (fr) Derivés de 2-(phenyl)-2h-pyrazol-3-acide carboxylique-n-4-(imino-heterocyclyl)-phenyl-amide et composes derivés servant d'inhibiteurs des facteurs de coagulation xa et/ou viia dans le traitement de thromboses
US6858617B2 (en) Substituted imidazole compounds
US9593096B2 (en) α7 nicotinic acetylcholine receptor modulators and uses thereof-III

Legal Events

Date Code Title Description
FZDE Dead